Abstract

Chronic Obstructive Pulmonary Disease (COPD) is defined by the Global initiative for chronic Obstructive Lung Disease (GOLD) as a common preventable and treatable disease, which is characterized by a persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response of the airways and lungs to noxious particles or gases. Since 2010, COPD is globally the third leading cause of death. Each year, approximately 200 000 to 300 000 people die in Europe because of COPD. The morbidity, economic and social impact of COPD is substantial and increasing.2 Among respiratory diseases, COPD is the leading cause of lost work days and it has an estimated cost of 3 to 4% (or 38.6 billion €) of the total health care budget in the European Union.

Additional Metadata
Keywords COPD, lung diseases, respiratory diseases, inflammation, inflammatory response
Promotor G.G. Brusselle (Guy) , B.H.Ch. Stricker (Bruno)
Publisher Erasmus University Rotterdam
Sponsor Financial support by the Fund for Scientific Research Flanders (Grants 3G019309 and G035014N) and travel fellowships from the Belgian Thoracic Society and European Respiratory Society are gratefully acknowledged. The Rotterdam Study or part of this thesis was supported by the Erasmus Medical Center, Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organisation for Health Research and Development (ZonMw), the Netherlands Heart Foundation, the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Genomics Initiative (NGI), the Ministry of Education, Culture and Science; the Ministry of Health Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam.
Persistent URL hdl.handle.net/1765/77125
Citation
Lahousse, L. (2014, November 11). Epidemiology of Comorbidities in Chronic Obstructive Pulmonary Disease. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/77125